Deliyannis, Georgia, Wong, Chinn Yi, McQuilten, Hayley A., Bachem, Annabell, Clarke, Michele, Jia, Xiaoxiao, Horrocks, Kylie, Zeng, Weiguang, Girkin, Jason, Scott, Nichollas E., Londrigan, Sarah L., Reading, Patrick C., Bartlett, Nathan W., Kedzierska, Katherine, Brown, Lorena E., Mercuri, Francesca, Demaison, Christophe, Jackson, David C., Chua, Brendon Y.. American Society for Clinical Investigation; 2021. TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs.

Proud, Pamela C., Tsitoura, Daphne, Watson, Robert J., Chua, Brendon Y., Aram, Marilyn J., Bewley, Kevin R., Cavell, Breeze E., Cobb, Rebecca, Dowall, Stuart, Fotheringham, Susan A., Ho, Catherine M. K., Lucas, Vanessa, Ngabo, Didier, Rayner, Emma, Ryan, Kathryn A., Slack, Gillian S., Thomas, Stephen, Wand, Nadina I., Yeates, Paul, Demaison, Christophe, Zeng, Weiguang, Holmes, Ian, Jackson, David C., Bartlett, Nathan W., Mercuri, Francesca, Carroll, Miles W.. The Lancet Publishing Group; 2021. Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.